Dr. Robert Molpus

Psychiatry
Patricia W Brown PhD ARNP LLC
618 E South St Ste 100, 
Orlando, FL 
Patricia W Brown PhD ARNP LLC
618 E South St Ste 100, 
Orlando, FL 

Overview

Robert Molpus is a Psychiatrist in Orlando, Florida. His top area of expertise is Attention Deficit Hyperactivity Disorder (ADHD).

His clinical research consists of participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Psychiatry

Licenses

Psychiatry & Neurology in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Patricia W Brown PhD ARNP LLC
618 E South St Ste 100, Orlando, FL 32801

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder
A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: April 13, 2026
Intervention Type: Drug, Other
Study Drugs: Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride
Study Phase: Phase 4
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
PROSPER-FM: Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management
PROSPER-FM: Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management
Enrollment Status: Completed
Publish Date: June 15, 2023
Intervention Type: Device, Other
Study Phase: Phase 3
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: July 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: June 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
An 8-Week Prospective Randomized, Controlled, Double-Blind Trial of the Genecept Assay ™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With Major Depressive Disorder (MDD)
An 8-Week Prospective Randomized, Controlled, Double-Blind Trial of the Genecept Assay ™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With Major Depressive Disorder (MDD)
Enrollment Status: Completed
Publish Date: August 28, 2020
Intervention Type: Genetic, Other
Study Phase: Not Applicable
12 Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From A Major Depressive Disorder (MDD) Having Had- Within the Current Episode- An Inadequate Response to at Least One Medication Included in GeneSight Psychotropic
12 Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From A Major Depressive Disorder (MDD) Having Had- Within the Current Episode- An Inadequate Response to at Least One Medication Included in GeneSight Psychotropic
Enrollment Status: Completed
Publish Date: January 14, 2020
Intervention Type: Genetic
Study Phase: Not Applicable
View 9 Less Clinical Trials
Similar Doctors
Expertise in
6
conditions
Dr. Luis Allen
Psychiatry
Expertise in
6
conditions
Dr. Luis Allen
Psychiatry

Central Florida Geriatric Psychiatry Inc

425 W Colonial Dr Ste 302, 
Orlando, FL 
 (8.8 miles away)
407-362-5459
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Luis Allen is a Psychiatrist in Orlando, Florida. Dr. Allen is highly rated in 6 conditions, according to our data. His top areas of expertise are Major Depression, Bipolar Disorder (BPD), Seasonal Affective Disorder (SAD), and Schizoaffective Disorder.

Expertise in
5
conditions
Dr. Sofia Qadir
Psychiatry
Expertise in
5
conditions
Dr. Sofia Qadir
Psychiatry

Hope Centers Of Central Florida LLC

101 E Miller St, 
Orlando, FL 
 (12.2 miles away)
407-246-6621
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sofia Qadir is a Psychiatrist in Orlando, Florida. Dr. Qadir is highly rated in 5 conditions, according to our data. Her top areas of expertise are Schizoaffective Disorder, Schizophrenia, Bipolar Disorder (BPD), and Major Depression.

Expertise in
11
conditions
Dr. Tanveer Chaudhry
Psychiatry
Expertise in
11
conditions
Dr. Tanveer Chaudhry
Psychiatry

Office

17222 Hospital Blvd Ste 226, 
Brooksville, FL 
 (61.0 miles away)
352-397-4481
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tanveer Chaudhry is a Psychiatrist in Brooksville, Florida. Dr. Chaudhry is highly rated in 11 conditions, according to our data. His top areas of expertise are Post-Traumatic Stress Disorder (PTSD), Bipolar Disorder (BPD), Seasonal Affective Disorder (SAD), and Generalized Anxiety Disorder (GAD).

Frequently Asked Questions about Dr. Robert Molpus

How do I make an appointment with Dr. Robert Molpus?

You can book an appointment with Dr. Robert Molpus by calling their office at 407-425-5100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Robert Molpus a top-rated expert for Attention Deficit Hyperactivity Disorder (ADHD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Robert Molpus is classified as an Experienced expert for Attention Deficit Hyperactivity Disorder (ADHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Robert Molpus specialize in?

While Dr. Robert Molpus is a Psychiatry, they have specific expertise in Attention Deficit Hyperactivity Disorder (ADHD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Psychiatry.

Does Dr. Robert Molpus accept my insurance?

Dr. Robert Molpus accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 407-425-5100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Molpus's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile